MAP - Market Access Podcast
Episodes
Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?
15 Mar 2022
Contributed by Lukas
The Italian reimbursement system is unique in terms of its structure, especially also for innovative drugs. However, wha...
What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?
01 Mar 2022
Contributed by Lukas
The Austrian market access pathway in the outpatient setting is unique in its pragmatic approach with their box system.The two experts on the Austrian...
The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?
15 Feb 2022
Contributed by Lukas
The German health care system consists of the statutory and private health insurances, whereas the latter covers around 10% of the population. Anyhow,...
How can a company derive the optimal price for their medical product, Dr. Renato Dellamano?
01 Feb 2022
Contributed by Lukas
What are drivers of pricing and ultimately negotiations? How can a global strategy best be implemented in individual countries? How do payers react to...
How do innovations reach patients in German hospitals, Dr. Sebastian Casu?
15 Jan 2022
Contributed by Lukas
How important are the famous NUBs, OPS and DRG values? How can innovations reach patients beyond administrative barriers? What are the next steps in t...
How does hospital funding work in Germany, Willi Wöllner?
01 Jan 2022
Contributed by Lukas
How does reimbursement work in the German hospital setting and how are hospitals organized doing such negotiations? What is a NUB and how do...
Prof. Dr. Jürgen Wasem - What happens, when negotiations fail?
15 Dec 2021
Contributed by Lukas
Who could be better to tell us the real insights, how the arbitration board works than Prof. Dr. Juergen Wasem, the former head of the AMNOG...
Dr. Michael Zuercher - Commercial attractiveness of the Swiss health care market – success starts with market access.
01 Dec 2021
Contributed by Lukas
In this Podcast episode Dr. Stefan Walzer confronts the Swiss expert Michael Zuercher with his perspective on Market Access to Switzerland. Furthermor...
Prof. Peter Zweifel & Door Vonk - Digital innovation - from theory into practice!
15 Nov 2021
Contributed by Lukas
In this Podcast episode, Dr. Stefan Walzer is discussing innovation theory from an economics perspective together with Prof. Peter Zweifel from the Un...
Bibiane Schulte-Bosse - How to fight well in AMNOG negotiations.
01 Nov 2021
Contributed by Lukas
In this Podcast episode, Dr. Stefan Walzer is explaining the details of the price negotiations within the AMNOG process together with negotiating expe...
Prof. Dr. David Matusiewicz & Dr. Anne Sophie Geier - 1 year DIGAs. Is the "fast track process" for digital health applications successful?
15 Oct 2021
Contributed by Lukas
In this Podcast episode, Dr. Stefan Walzer is reflecting on 1 year DIGAswith the leading question whether the "fast track process" for digital health ...
Remo Christen – Early paid access in Switzerland – Switzerland, wonderland??
01 Oct 2021
Contributed by Lukas
In this Podcast episode, Dr. Stefan Walzer is discussing the specifics of the Swiss market access & reimbursement specifics including the famous a...
Prof. Dr. Wagschal - What can we expect from the upcoming elections in Germany?
15 Sep 2021
Contributed by Lukas
In this Podcast episode, Dr. Stefan Walzer is speaking to Prof. Dr. Wagschal from the University of Freiburg about the upcoming elections in Germany.T...
Dr. Mathias Flume - AMNOG will change in 2022, but how?
02 Sep 2021
Contributed by Lukas
In this Podcast episode, Dr. Stefan Walzer is talking with Dr. Mathias Flume about the AMNOG process as well as interesting details about the market a...